Company intelligence / Profile preview

Evoke Pharma, Inc.

Solana Beach, California, United Statesevokepharma.com ↗

Ownership: Public · EVOK
Employees: ~3
Development stage: Commercial

Overview

Evoke developed and commercialized Gimoti®, the first nasally administered metoclopramide formulation approved by FDA for relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company is advancing EVK‑001 through Phase 3 trials aiming to improve treatment options in this space[1][2][5].

Therapeutic areas: Endocrinology
Modalities: Nasal spray formulation of metoclopramide (small molecule drug delivery via nasal route)
Industry: Biotech

Drug pipeline

1 asset

metoclopramide

Commercial

Indications: Diabetic gastroparesis

Partnerships

Contract Research Organization SynteractHCR selected for Phase 3 trial management[2]

Financials

Market cap: $18.9M
Total revenue: $4.3M
Enterprise value: $12.5M

Beyond the preview

Go deeper on Evoke Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evoke Pharma, Inc..

Explore the full profile